China Biologic Receives Higher Counter Bid From Investor Group Led By Ex-CEO

Eudora Wang
August 21, 2018 — 14:26 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: bank bank of china Beijing biopharma industry biotech CDH Investments China China Biologic chinese CITIC CITIC Capital finance GL Capital Group insurance investment manufacturing pharmaceutical revenue stock market technology War

Related News:

Saudi Public Investment Fund (PIF) Reveals Plans to Open New Offices in China

December 13, 2023 — 02:00

Saudi Arabia’s FoFs Jada Backs eWTP Arabia Capital’s Second Fund

December 9, 2023 — 02:30

China To Expand Investment Scope for Its National Social Security Fund

December 8, 2023 — 00:03

Chinese Charitable Foundations Expand Into Alternative Investments To Enhance Returns

November 30, 2023 — 23:50

Bahrain’s Investcorp Targets RMB2-4 Billion Buyout Fund in China

November 25, 2023 — 00:58

Middle Eastern Sovereign Wealth Funds Deepen Investment in China

November 10, 2023 — 23:35

AI-Driven Pharmaceutical Startups Attract Soaring Investor Interest

November 5, 2023 — 03:24

KKR Leads $180 Million Series F Round In Newly-Minted Asian Unicorn Livspace

February 15, 2022 — 03:32

Yufeng Capital: Expect To Live To 120 Years As China Realizes Digital Healthcare

April 24, 2021 — 04:25

Franchising and Licensing Asia (FLAsia) 2024